Page 39 - 2019_08-Haematologica-web

Promising targets for MRD therapies in AML
Clin Oncol. 2012;30(32):3924-3931.
104. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta- analysis of individual patient data from ran- domised controlled trials. Lancet Oncol.
2014;15(9):986-996.
105.Burnett A, Cavenagh J, Russell N, et al.
Defining the dose of gemtuzumab ozogam- icin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial. Haematologica. 2016;101(6):724-731.
106.Lambert J, Lambert J, Nibourel O, et al. MRD assessed by WT1 and NPM1 tran- script levels identifies distinct outcomes in AML patients and is influenced by gem- tuzumab ozogamicin. Oncotarget. 2014;5 (15):6280-6288.
107.Laszlo GS, Gudgeon CJ, Harrington KH, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T- cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123(4): 554-561.
108. Ravandi F, Stein, AS, Kantarjian, HM, et al. A Phase 1 first-in-human study of AMG 330, an anti-CD33 bispecific T-cell engager (BiTE®) antibody construct, in relapsed/refractory acute myeloid leukemia (R/R AML) ASH Annual Meeting 2018.
109.Munoz L, Nomdedeu JF, Lopez O, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malig- nancies. Haematologica. 2001;86(12):1261- 1269.
110.Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myeloge- nous leukemia stem cells. Leukemia. 2000;14(10):1777-1784.
111.Kovtun Y, Jones GE, Adams S, et al. A
CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood advances. 2018;2(8):848-858.
112. Daver NG, Erba HP, Papadantonakis N, et al. A phase I, first-in-human study evaluating the safety and preliminary antileukemia activity of IMGN632, a novel CD123-target- ing antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia and other CD123-positive hema- tologic malignancies. ASH Annual Meeting 2018. Blood. 2018;132(Suppl 1):27.
113. Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to inter- leukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385-392.
114.Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendrit- ic-cell neoplasm. 2019;380(17):1628-1637.
115.van Rhenen A, van Dongen GAMS, Kelder A, et al. The novel AML stem cell–associat- ed antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110(7):2659.
116. Van Loo PF, Doornbos R, Dolstra H, Shamsili S, Bakker L. Preclinical evaluation of MCLA117, a CLEC12AxCD3 bispecific antibody efficiently targeting a novel leukemic stem cell associated antigen in AML. Blood. 2015;126(23):325.
117. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379 (1):64-73.
118. Ritchie DS, Neeson PJ, Khot A, et al. Persistence and efficacy of second genera- tion CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21(11):2122-2129.
119.Kenderian SS, Ruella M, Shestova O, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
Leukemia. 2015;29(8):1637-1647.
120. Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target pri- mary acute myeloid leukemia cells in vivo.
Leukemia. 2014;28(8):1596-1605.
121. Gill S, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood.
2014;123(15):2343-2354.
122. Tashiro H, Sauer T, Shum T, et al. Treatment
of acute myeloid leukemia with T cells expressing chimeric antigen receptors direct- ed to C-type lectin-like molecule 1. Mol Ther. 2017;25(9):2202-2213.
123.Perna F, Berman SH, Soni RK, et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric anti- gen receptor therapy of AML. Cancer Cell. 2017;32(4):506-519 e505.
124.Kim MY, Yu K-R, Kenderian SS, et al. Genetic inactivation of CD33 in hematopoi- etic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 2018;173(6):1439-1453.e1419.
125.Khoury HJ, Collins RH, Jr., Blum W, et al. Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. Cancer. 2017;123(16):3061-3072.
126.van de Loosdrecht AA, van Wetering S, Santegoets S, et al. A novel allogeneic off- the-shelf dendritic cell vaccine for post- remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunol Immunother. 2018;67(10):1505-1518.
127.Lambert J, Pautas C, Terré C, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104 (1):113.
haematologica | 2019; 104(8)
1531